EMPLICURE INTERIM REPORT JANUARY-SEPTEMBER 2021 – BUILDING A STRONG TEAM AND A FOUNDATION FOR GROWTH
2021-11-19 07:30
Following this summer's new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company's two main projects; Empli03, our drug candidate for chronic pain, and Amp01, our oral tobacco-free nicotine product in the form of dry, white pouches as a consumer product. Both projects are developed on our own bioceramic and patented technologies and platforms.
Third quarter, 1 July – 30 September 2021
· Net revenue totalled 0.0 (0.1) MSEK
· EBIT totalled -3.7 (-0.8) MSEK
· EBITDA totalled -4.3 (-0.8) MSEK
· Cash flow totalled 20.1 (-0.2) MSEK
· Earnings per share -0.42 (-0.08) SEK
Accumulated, 1 January – 30 September 2021
· Net revenue totalled 0.1 (0.2) MSEK
· EBIT totalled -10.9 (-3.0) MSEK
· EBITDA totalled -13.3 (-3.0) MSEK
· Cash flow totalled 23.4 (1.8) MSEK
· Earnings per share -1.29 (-0.30) SEK
· Emplicure was listed on Nasdaq First North Growth Market
Adviser
Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se
For more information, please contact:
|
Torbjörn W. Larsson |
Anna-Lena Nicolson |
This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on November 19, 2021 at 08:30 CET.
The following documents can be retrieved from beQuoted
PM-INTERIM-REPORT-Q3-2021-BUILDING-A-STRONG-TEAM-AND-A-FOUND.pdf
INTERIM-REPORT-Q3-2021-BUILDING-A-STRONG-TEAM-AND-A-FOUNDATI.pdf
Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Emplicure is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com